


Stabilis



Reteplase



Tradename

Rapily sine	Austria, Belgium, Denmark, Italy, Netherlands, Portugal, Spain, Sweden
Retavase	United States of America



Stability in solutions

		1 UI/ml	2-30°C		8			2212



Compatibility

		Reteplase Acetylsalicylic acid lysinate		2212
		Reteplase Bivalirudin		3539
		Reteplase : 1 UI/ml Bivalirudin : 5 mg/ml		1713
		Reteplase Heparin sodium		2212
		Reteplase Heparin sodium		3540



Route of administration

































References

	Type	Publication
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
2212	Manufacturer	Reteplase (Rapilysin®) - Summary of Product Characteristics Actavis UK Ltd 2015
3539	Manufacturer	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Manufacturer	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010



Dictionary

 Thrombolytic	 Injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 Conflicting data
 References	 Glass
 Water for Injection	 Not specified
 Hour	 Compatibility
 Compound	 Solvent
 Unspecified incompatibility	 Incompatible
 Immediate precipitation	 Glucose 5%
 Route of administration	 Intravenous
 References	 Dictionary